The arm of the EU responsible for proposing legislation has proposed a vastly disproportionate approach to regulating electronic cigarettes. It’s so extreme that it isn’t going too far to suggest that, if enacted, it would constitute a ban of the vast majority of electronic cigarettes on the market. If you’re an EU vaper and you happen to vape delicious flavours, buy anything from other countries, use tanks or refillable cartridges or buy e-liquids of over 20 mg / ml of nicotine, you can kiss your electronic cigarettes goodbye. Needless to say, opposing this proposed legislation is essential for any concerned EU vapers.
What The Commission is Suggesting
There are a wide range of disturbing suggestions in the EU Commission’s proposed legislation, including:
- A maximum e-liquid nicotine concentration of 20 mg / ml (despite the EU Parliament’s suggested 30 mg / ml limit).
- No refillable cartridges or tanks will be allowed – single-use cartomizers only.
- No more than 10 mg of nicotine in any single cartridge.
- No flavours which aren’t already available in NRT (for example, Nicorette gum is available in a pathetic four flavours), “unless such a flavour is particularly attractive to young people and non-smokers.”
- Demands that electronic cigarettes only “deliver nicotine doses consistently and uniformly.”
- Only high-purity ingredients free from contaminants are to be used in e-liquid manufacture.
- Bans any cross-border sales (so, no buying components from other countries online).
- Bans advertising except in trade publications, or “any form of public or private contribution to any event, activity or individual with the aim or direct or indirect effect of promoting electronic cigarettes” so long as they involve or take place in several member states.
- Requests that manufacturers and importers collect and provide a wide range of information, including annual sales volumes, information on the preferences of consumer groups such as non-smokers and young.
- Manufacturers, importers or distributors would have to establish and maintain a system to collect information about all suspected adverse effects.